ACT receives patent for its single-blastomere technology Advanced Cell Technology, Inc medicina . , a leader in the field of regenerative medication, announced today that it has been issued a patent on its ‘single-blastomere’ technique.’ The single-blastomere technology runs on the one-cell biopsy approach identical to pre-implantation genetic medical diagnosis , which is trusted in the in vitro fertilization process and does not hinder the embryo’s developmental potential.D., chief scientific officer of ACT, stated, ‘This patent issuance represents acknowledgement of the development underlying our single-blastomere technology. Furthermore, this IP protection comes after on the issuance of a broad patent associated with ACT’s creation and therapeutic usage of Retinal Pigment Epithelial cells this year 2010.
The update includes details on seven topics – including ACOs also, bundled payments, and health plan administrative simplification – not really previously covered but shown to be of interest predicated on questions and curiosity by internists and their patients. The Internist’s Guide features a two-page desk of contents with hyperlinks that take viewers directly to provisions within the guidebook. They can access areas of interest by placing the cursor over provided provisions in the desk of contents, and clicking with the mouse. The document is in a ‘searchable’ format, which allows viewers to find items of interest using key term and phrases. Related StoriesPreventing falls in treatment homes: an interview with Professor Pip LoganWHO focused on helping Nepal deliver healthcare to its citizens, says WHO South-East Asia Regional DirectorInnovative IV pole making use of polycarbonate resin blend from Bayer enhances patient and health care worker safetyAs a living document, the information will continue to be up to date by ACP as developments occur and queries about the law are elevated and answered.